Intranasal insulin — Competitive Intelligence Brief

Intranasal insulin (Intranasal insulin) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Insulin preparation. Area: Diabetes.

phase 3 Insulin preparation Insulin receptor Diabetes Small molecule

Target snapshot

Intranasal insulin (Intranasal insulin) — University Health Network, Toronto. Intranasal insulin delivers insulin directly to the nasal mucosa for systemic absorption, bypassing first-pass hepatic metabolism to improve glycemic control.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Intranasal insulin TARGET	Intranasal insulin	University Health Network, Toronto	phase 3	Insulin preparation	Insulin receptor
Tresiba	INSULIN DEGLUDEC	Novo Nordisk	marketed	Insulin Analog [EPC]	Insulin receptor	2015-01-01
Levemir	INSULIN DETEMIR	Novo Nordisk	marketed	Insulin Analog [EPC]	Insulin receptor	2005-01-01
Apidra	INSULIN GLULISINE	Sanofi	marketed	Insulin Analog [EPC]	Insulin receptor	2004-01-01
Lantus	INSULIN GLARGINE	Sanofi	marketed	Insulin Analog [EPC]	Insulin receptor	2000-01-01
Novolog	INSULIN ASPART	Novo Nordisk	marketed	Insulin Analog [EPC]	Insulin receptor	2000-01-01
Humalog	INSULIN LISPRO	Eli Lilly	marketed	Insulin Analog [EPC]	Insulin receptor	1996-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Insulin preparation class)

1. Eli Lilly and Company · 1 drug in this class
2. University Health Network, Toronto · 1 drug in this class